Acceleron's pulmonary hypertension treatment meets
main goal, shares soar 79%
Send a link to a friend
[January 28, 2020]
(Reuters) - Acceleron Pharma Inc <XLRN.O>
said on Monday its investigational treatment for a rare, deadly lung
disease called pulmonary arterial hypertension met the main goal in a
mid-stage trial, sending its shares surging 79%.
The treatment, sotatercept, showed significant reduction in
pulmonary vascular resistance versus placebo at week 24.
It also showed significant improvements in patients functional
capacity, which was determined by a six minute walk test.
Pulmonary arterial hypertension, or PAH, occurs when arteries in the
lungs constrict, forcing the heart to work harder, often leading to
heart failure. Its symptoms include shortness of breath and fatigue.
[to top of second column]
The disease has no cure, but there are treatments on the market that
can manage the condition.
The company has a rare blood disorder drug, Reblozyl, in the market.
(Reporting by Dania Nadeem in Bengaluru; Editing by Shinjini Ganguli)
[© 2020 Thomson Reuters. All rights
Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.